To describe two patients with macular edema secondary to tuberous sclerosis complex (TSC), who were treated with intravitreal bevacizumab injection.
Introduction
Tuberous sclerosis complex (TSC) is a syndrome characterized by hamartomatous growths in multiple organs (Roach et al. 1998) . Patients with TSC generally develop retinal astrocytic hamartomas; however clinical symptoms of patients with the retinal hamartomas are generally asymptomatic and most astrocytic hamartomas remains unchanged in size or regress during life (Zimmer-Galler & Robertson 1995) .
Symptomatic ocular complications rarely represent and include macular edema, exudative retinal detachment (RD), vitreous hemorrhage (VH), and neovascular glaucoma (Mennel et al. 2007 ). Symptomatic macular edema or exudative RD has previously been reported in only 7 eyes (Mennel et al. 2007 ). Argon laser photocoagulation or photodynamic therapy against retinal hamartoma may be effective for these complications (Bloom & Mahl 1991; Mennel et al. 2007 ). However, multiple laser treatment procedures may cause laser-induced choroidal neovascularization (Bloom & Mahl 1991) . Thus, the therapeutic strategy for macular edema secondary to TSC, and the pathogenic mechanism are controversial. We report two patients with macular edema/ exudative RD secondary to TSC who underwent intravitreal 6 6 bevacizumab injection, from the result of high intravitreal vascular endothelial growth factor (VEGF) levels in one patient.
Case reports

Case 1
In 1995, a 22-year-old woman with TSC was referred for ophthalmologic examination.
At 8 years of age, the patient was diagnosed as having TSC based on clinical findings including facial angiofibromas, renal angiomyolipoma, and subependymal nodules. Her visual acuities was 20/30 OD, and 20/15 OS. Anterior segment and lens were clear, OU. Funduscopy revealed macular exudative RD with lipoid exudates and an elevated, oval-shaped whitish retinal tumor without calcification, located in parapapillary area (Fig. 4A ). The tumor located on the retinal surface and involved neovascularization on the surface (Fig. 4A, arrow) . Late-phase FA revealed marked leakage from the tumor, the neovascularization, and retinal capillary vessels (Fig. 4B) . A diagnosis of retinal hamartoma type 1 in association with TSC was made. One month later, exudative RD spontaneously regressed and visual acuity improved to 20/20, OD. However, the neovascularization originated from the tumor remained unchanged. Since we considered that the neovascularization caused VH like case 1, after informed consent, the patient received intravitreal bevacizumab 1.25 mg injection. One week after the injection, the tumor size reduced with regression of the neovascularization (Fig. 5A) . The late leakage from the tumor and retinal capillary vessels in FA decreased (Fig. 5B ). Three months after the injection, the tumor almost regressed (Fig. 5C ) and visual acuity increased of 10 20/ 16, OD.
Discussion
TSC has been determined to result from mutations in TSC1 (hamartin) and TSC 2 (tuberin) tumor suppressor gene (Cheadle et al 2000) . TSC1 and TSC2 proteins are responsible for the regulation of cell growth and tumourigenesis: TSC1/ TSC2 complex controls Ras homologue enriched in brain (Rheb) and subsequently inhibits the mammalian target of rapamycin (mTOR), a key regulator in signaling pathway of cell proliferation and organ size (Schwartz et al 2007) . Therefore, mutated TSC1/TSC2 complex causes uncontrolled cell growth and proliferation. Moreover, it is elucidated that hamartomas associated with TSC, involving the other organs (kidney, brain, and skin) except the eyes, are highly angiogenic (Arbiser et al. 2002) and can express angiogenic factors including VEGF (Nguyen-Vu et al. 2001) . However, as far as we know, there are no reports which detected expression of VEGF in retinal hamarotmas.
Therefore, we hypothesized that retinal hamartomas are also highly angiogenic and express VEGF, which lead to ocular complication including macular edema.
In this study, VEGF concentration in the vitreous fluid taken intraoperatively in case 11 11 1 was apparently high, compared to the levels in patients without retinal vascular diseases. Retinal hamartomas in two patients involved VH (case 1) and the neovascularization originated from retinal tumors (case 2), suggesting that retinal hamartomas associated with TSC are well-vascularized tumors and possibly express VEGF. Based on the result of high intravitreal VEGF concentration in case 1, intravitreal bevacizumab injection was tried in two patients with TSC-associated macular edema/ exudative RD. After injection, not only macular edema, VA, OCT, and FA findings rapidly improved (Case 1) but the tumor size and tumor-associated neovascularization were rapidly attenuated (Case 2), although these two patients possibly may have recurrence of macular edema after a long-term follow-up. Therefore, the results in this study strongly suggest that VEGF derived from retinal astrocytic hamartomas plays a potential role in the pathogenesis of macular edema/ exudative RD secondary to TSC. As far as we know, there are no reports demonstrating effectiveness of intravitreal bevacizumab injection in patients with TSC-associated macular edema.
In both patients 1 and 2, macular oedema disappeared rapidly by a single intravitreal bevacizumab injection. However, macular oedema secondary to TSC may be repeated, 12 such as in patient 1, in a long-term follow-up.When macular oedema recurred, performing intravitreal bevacizumab injection 3-6 times continuously every 4-6 weeks may be considered (Soliman et al. 2008) . Moreover, additional retinal photocoagulation or photodynamic therapy for tumours causative of exudation may also be considered after intravitreal bevacizumab injection. When we follow up patients with TSC, to detect initial or recurrent macular oedema in early stage by performing OCT regularly is mandatory for preventing poor visual prognosis (Massin et al. 2006 ).
In conclusion, intravitreal anti-VEGF antibody injection including bevacizumab might be a therapeutic option for macular edema/ exudative RD secondary to TSC. 
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